Carroll Financial Associates’s Charles River Laboratories CRL Stock Holding History

Carroll Financial Associates’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$72K	Buy	192 +13	+7%	+$5.05K	﹤0.01%	614
2021 Q3	$73K	Sell	179 -220	-55%	-$91.4K	﹤0.01%	627
2021 Q2	$147K	Buy	399 +225	+129%	+$75.1K	0.01%	489
2021 Q1	$50K	Buy	174 +53	+44%	+$14.7K	﹤0.01%	769
2020 Q4	$30K	Hold	121	–	–	﹤0.01%	818
2020 Q3	$27K	Buy	121 +114	+1,629%	+$23.7K	﹤0.01%	791
2020 Q2	$1K	Sell	7 -1	-13%	-$160	﹤0.01%	1410
2020 Q1	$1K	Hold	8	–	–	﹤0.01%	1348
2019 Q4	$1K	Hold	8	–	–	﹤0.01%	1426
2019 Q3	$1K	Hold	8	–	–	﹤0.01%	1394
2019 Q2	$1K	Hold	8	–	–	﹤0.01%	1440
2019 Q1	$1K	Buy	+8	New	+$1.05K	﹤0.01%	1288

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Carroll Financial Associates's CRL Position: Q4 2021 in Review

Carroll Financial Associates increased its Charles River Laboratories (CRL) stake by 7.3% in Q4 2021, buying an estimated $5.05K and bringing the position to 192 shares worth $72K. The position accounts for ﹤0.01% of the portfolio, ranked #614.

Carroll Financial Associates first reported a position in CRL in Q1 2019 and has held it in 12 quarters since. The position peaked at $147K in Q2 2021. 708 funds tracked by Wall St. Rank hold CRL as of Q4 2021.

Carroll Financial Associates held 192 shares of Charles River Laboratories worth $72K as of Q4 2021.
Carroll Financial Associates bought 13 Charles River Laboratories shares in Q4 2021, an estimated $5.05K.
Charles River Laboratories made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #614 holding.
Carroll Financial Associates first reported a position in Charles River Laboratories in Q1 2019 and has held it in 12 quarters since.
Carroll Financial Associates's Charles River Laboratories position peaked at $147K in Q2 2021.
708 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.